0001317757-11-000029.txt : 20111220
0001317757-11-000029.hdr.sgml : 20111220
20111220160452
ACCESSION NUMBER: 0001317757-11-000029
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20111219
FILED AS OF DATE: 20111220
DATE AS OF CHANGE: 20111220
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: White Christopher G
CENTRAL INDEX KEY: 0001537668
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-10865
FILM NUMBER: 111272130
MAIL ADDRESS:
STREET 1: C/O AMAG PHARMACEUTICALS, INC.
STREET 2: 100 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMAG PHARMACEUTICALS INC.
CENTRAL INDEX KEY: 0000792977
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 042742593
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 6174983300
MAIL ADDRESS:
STREET 1: 100 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: ADVANCED MAGNETICS INC
DATE OF NAME CHANGE: 19920703
3
1
primary_doc.xml
PRIMARY DOCUMENT
X0204
3
2011-12-19
0
0000792977
AMAG PHARMACEUTICALS INC.
AMAG
0001537668
White Christopher G
C/O AMAG PHARMACEUTICALS, INC.
100 HAYDEN AVENUE
LEXINGTON
MA
02421
0
1
0
0
Chief Business Officer and SVP
Stock Options
54.66
2017-09-04
Common Stock
15000
D
Stock Options
47.08
2018-02-26
Common Stock
14000
D
Restricted Stock Units
Common Stock
3750
D
Stock Options
34.26
2019-02-25
Common Stock
20000
D
Restricted Stock Units
Common Stock
2500
D
Stock Options
38.29
2020-02-24
Common Stock
10000
D
Restricted Stock Units
Common Stock
16000
D
Restricted Stock Units
Common Stock
4000
D
Grant of stock option pursuant to the AMAG Pharmaceuticals, Inc. Amended and Restated 2000 Stock Plan. This grant vested in four equal installments on September 4, 2008, September 4, 2009, September 4, 2010 and September 4, 2011.
Grant of stock option pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in four equal installments. Installments one, two and three vested on February 26, 2009, February 26, 2010 and February 26, 2011, respectively. The fourth installment will vest on February 26, 2012.
Grant of 15,000 restricted stock units pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests as follows: 50% on August 5, 2010, 25% on August 5, 2011 and the remaining 25% on August 5, 2012.
Not applicable.
Each restricted stock unit represents a contingent right to receive one share of common stock.
Grant of stock option pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in four equal installments. Installments one and two vested on February 25, 2010 and February 25, 2011, respectively. The remaining two installments will vest on February 25, 2012 and February 25, 2013.
Grant of 3,333 restricted stock units pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in four equal installments. Installment one vested on February 24, 2011. Installments two, three and four will vest on February 24, 2012, February 24, 2013 and February 24, 2014, respectively.
Grant of stock option pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in four equal installments. Installment one vested on February 24, 2011. Installments two, three and four will vest on February 24, 2012, February 24, 2013 and February 24, 2014, respectively.
Grant of restricted stock unit pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests as follows: 50% on January 7, 2012, 25% on January 7, 2013 and the remaining 25% on January 7, 2014.
Grant of restricted stock unit pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in its entirety in a single installment on the earlier to occur of: January 7, 2015, or immediately prior to a change of control of the Company, provided that in either case the closing price of the Company's stock is at least $30.00 per share.
Joseph L. Farmer, attorney-in-fact
2011-12-20
EX-99
2
powerofattorney.txt
POWER OF ATTORNEY
POWER OF ATTORNEY
For Executing Forms 3, 4 and 5
Know all by these present,that the undersigned hereby
constitutes and appoints each of Frank Thomas and
Joseph Farmer, signing singly, his true and lawful
attorney-in-fact to:
(1) execute for and on behalf of the undersigned,in the
undersigneds capacity as an officer and/or director of
AMAG Pharmaceuticals, Inc., or the Company, Forms 3, 4 and 5
(including any amendments thereto) in accordance with Section
16(a) of the Securities Exchange Act of 1934,
as amended and the rules thereunder;
(2) do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to complete
the execution of any such Forms 3, 4 and 5 and the timely filing
of such forms with the United States Securities and Exchange
Commission and any other authority; and
(3) take any other action of any type whatsoever in connection
with the foregoing which,in the opinion of such attorney-in-fact
may be of benefit to,in the best interest of,or legally required
by,the undersigned,it being understood that the documents
executed by such attorney-in-fact on behalf of the undersigned
pursuant to this Power of Attorney shall be in such form and
shall contain such terms and conditions as such attorney-in-fact
may approve in his discretion.
The undersigned hereby grants to each such attorney-in-fact full
power and authority to do and perform all and every act and thing
whatsoever requisite, necessary and proper to be done in the
exercise of any of the rights and powers herein granted,as fully
to all intents and purposes as the undersigned might or could do
if personally present,with full power of substitution or revocation
hereby ratifying and confirming all that such attorney-in-fact, or
his substitute or substitutes, shall lawfully do or cause to be done
by virtue of this Power of Attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing
attorneys-in-fact, in serving in such capacity at the request of
the undersigned, are not assuming, nor is the Company assuming,
any of the undersigneds responsibilities to comply with Section 16
of the Securities Exchange Act of 1934, as amended.
This Power of Attorney replaces in their entirety any and all
prior powers of attorney executed by the undersigned with respect
to the subject matters set forth herein, including any powers of
attorney previously filed with the Securities and Exchange
Commission. This Power of Attorney shall remain in full force
and effect until the undersigned is no longer required to file
Forms 3, 4 and 5 with respect to the undersigneds holdings of and
transactions in securities issued by the Company, unless earlier
revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of
Attorney to be executed this 19th day of December 2011.
Signed: /s/ Christopher G. White
Please Print: Christopher G. White